

**MARKSANS PHARMA LIMITED [formerly Tasc Pharmaceuticals Ltd.]**

Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd, A.K.Road, Andheri [East], Mumbai-400099

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2005

(Rs. In lacs)

Sr. No.	PARTICULARS	Quarter ended		Nine months ended		Year ended
		31st Dec. 2005 (UNAUDITED)	31st Dec. 2004 (UNAUDITED)	31st Dec. 2005 (UNAUDITED)	31st Dec. 2004 (UNAUDITED)	31st March 05 (AUDITED)
1	Net sales /Income from Operations	7,209.18	6,531.03	24,683.35	16,725.29	25,289.56
2	Other Income	132.46	31.97	212.29	107.74	163.65
3	Total Expenditure	6,276.31	5,627.85	20,497.10	13,909.19	21,059.89
	-(Increase) /Decrease in Stock in trade	(1,389.28)	(664.37)	(814.33)	(781.37)	(1,522.46)
	-Consumption of Raw Material	6,601.62	5,356.75	18,030.16	11,875.42	18,647.40
	-Staff Cost	233.06	175.12	586.46	523.58	723.16
	-Other Expenditure	830.91	760.35	2,694.81	2,291.56	3,211.79
4	Interest	214.17	210.14	801.79	783.27	1,191.55
5	Depreciation	143.80	149.88	697.34	466.47	694.99
6	Profit/(Loss) before Ta	707.36	575.13	2,899.41	1,674.10	2,506.78
7	Provision for Taxation					
	a) Current	105.13	29.11	257.04	134.41	236.25
	b) Deferred	-	-	-	-	214.68
8	Net Profit /(Loss)	602.23	546.02	2,642.37	1,539.69	2,055.85
9	Add/Less :Short provision/ Prior period expenses	-	-	-	-	-
10	Net Profit/( after extra ordinary items)	602.23	546.02	2,642.37	1,539.69	2,055.85
11	Paid up Equity Share Capital (Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus ( Excluding Revaluation Reserve)	-	-	-	-	5,286.46
13	Basic and Diluted EPS for the period (Not annualised)	1.68	1.52	7.35	4.28	5.72
14	Non -Promoter share holding					
	-Number of Shares	18575527	6194800	18575527	6194800	8738000
	-Percentage of Share holding	51.68%	56.32%	51.68%	56.32%	69.90%

## Notes:

- 1 The above results were taken on records at the Board meeting held on 31-01-2006
- 2 EPS of the company, calculated on weighted average number of equity shares, is not annualised.
- 3 The details of investor complaints during the quarter is as under:  
Opening Balance : NIL, Received during the quarter : 13, Pending as on 31.12.05 : NIL
- 4 The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- 5 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

**For Marksans Pharma Limited**

Place: Mumbai

Date: 31st January, 2006

**Mark Saldanha**  
Managing Director